In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea
Why am I not losing weight on semaglutide after 3 weeks
Phase 4: Maintenance (Week 60+) What to expect: Weight stabilization and long-term management
Consult with our experts to find the most suitable option for your weight loss journey
At Seattle Plastic Surgery, we know some patients may hesitate to start a GLP-1 medication for weight loss because of injections
It plays an important role in controlling appetite, digestion, and overall metabolic function